Analysts at HC Wainwright issued their Q2 2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) on February 14 and set a price target of ...

H.C. Wainwright analyst Heiko Ihle reiterated a Buy rating on Hecla Mining Company (HL – Research Report) today and set a price target of ...

Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Tigo Energy in a research report ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. As of January 28, 2025, the average one-year price ...

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings NEW YORK, January 27, 2025--(BUSINESS WIRE)--H.C.